Overview of Diagnostic Autoantibodies in Inflammatory Myopathy
|
|
- Marcia Carter
- 6 years ago
- Views:
Transcription
1 Overview of Diagnostic Autoantibodies in Inflammatory Myopathy Minoru Satoh, M.D., Ph.D. Research Associate Professor of Medicine Division of Rheumatology and Clinical Immunology University of Florida
2 Disclosure none
3 Evidence-based Medicine (EBM) Anti-p155/140 (TIF1γ/α) 1. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54: Anti-MDA5/CADM Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60: Review on autoantibodies in inflammatory myopathy 3. Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol. 2010;5:
4 Clinical subsets of polymyositis/dermatomyositis (PM/DM) and autoantibodies (2004) Severe, Tx resistant myopathy Anti-synthetase antibody syndrome ILD Raynaud s Arthritis Good response to Tx
5 Clinical subsets of polymyositis/dermatomyositis (PM/DM) and autoantibodies (2012) Rapidly progressive ILD Amyopathic DM malignancy Calcinosis malignancy Satoh 2012
6 Anti-p155/140 (Transcription intermediary factor-1γ/α, TIF-1γ/α tripartite motif-containing, TRIM33/24)
7 Anti-p155/140 (Transcription intermediary factor-1γ/α, TIF-1γ/α, tripartite motif-containing, TRIM33/24)
8 Prevalence of anti-p155/140 (TIF-1γ/α, TRIM33/24) Category Clinical group Prevalence N = adult DM 21% 39 PM 0% 48 Overlap with other CTD 15% 13 Cancer-associated myositis 75% 8 Other 0% 9 Juvenile DM 29% 103 PM 0% 9 Overlap with other CTD 33% 15 all Non-PM/DM 0.7% 138 Targoff IN et al., Arthritis Rheum 2006, 54: 3682
9 Clinical features of anti-p155/140 (TIF-1γ/α) vs antisynthetase antibody positive PM/DM Feature Anti-p155/140 Anti-synthetase P value N = Fever 44% 87% Raynaud s phenomenon 19% 62% Arthritis 31% 94% Interstitial lung disease 0% 89% Mechanic s hands 25% 71% V-sign rash 75% 15% Shawl-sign rash 56% 7% Malignancy 38% (0%) Targoff IN et al., Arthritis Rheum 2006, 54: 3682
10 Anti-p155/140 (transcription intermediary factor, TIF-1γ/α, tripartite motif-containing, TRIM33/24) p155/140(tif-1γ/α) and β interact and function as a tumor suppressor. Found in ~20-30% of DM but ~0% in PM or other diseases Found in % of cancer-associated DM % of anti-p155/140 (+) DM have cancer Negative association with fever, lung disease, arthritis, Raynaud s phenomenon, Very similar clinical association in 8 studies from 5 countries
11 Anti-p155/140 (TIF-1γ/α) - Meta analysis Trallero-Araguas E et al., Arthritis Rheum. 2012;64(2):523-32
12 Anti-TIF-1β (transcription intermediary factor-1β, TRIM28) Satoh M et al., Arthritis Res Ther. 2012;14(2):R79 Fujimoto M et al., Arthritis Rheum. 2012;64(2):513-22
13 Anti-TIF1β (transcription intermediary factor-1β) Satoh M et al., Arthritis Res Ther. 2012;14(2):R79 Fujimoto M et al., Arthritis Rheum. 2012;64(2): Associated with mild DM May coexist with anti-tif-1γ/α (Japanese study) Association with malignancy is not as strong as anti-tif1γ/α (p155/p140)
14 Anti-CADM140 (clinically amyopathic dermatomyositis140) MDA5 (melanoma differentiation associated gene 5) IFIH1 (interferon induced with helicasec domain 1)
15 Anti-CADM140 (clinically amyopathic dermatomyositis)/ MDA5 (melanoma differentiation associated gene 5) ~140kD single protein ANA weak cytoplasmic staining or negative MDA5 is a cytoplasmic innate immune receptor for viral RNA Stimulation of MDA5 induces type I interferon Levels of anti-mda5 goes down after Tx Patients with high levels of anti-mda5 are resistant to Tx (Gono T, et al., Rheumatology 2012, Sato S et al., Mod Rheuma 2012)
16 Anti-CADM140/MDA5 antibodies are highly specific for C-ADM (clinically amyopathic DM) Sato S et al., Arthritis Rheum. 2009;60(7):
17 Anti-CADM140 (clinically amyopathic dermatomyositis140) /MDA5 (melanoma differentiation associated gene 5) Dermatomyositis Strong association with clinically amyopathic dermatomyositis (CADM) ~10% in DM 38-70% in CADM % of anti-cadm140 positive have CADM Associated with rapidly progressive interstitial lung disease and poor prognosis. Reports are mainly from Japan US study DM with severe skin disease
18 Two subsets of ILD in myositis defined by autoantibodies Prevalence of autoantibodies Anti-synthetase Anti-MDA5 ~30% in PM/DM ~10% in DM ~40-70% in C-ADM Prevalence of ILD 70-95% 50-90% Type of ILD Chronic or subacute Acute progressive pathology Mostly NSIP UIP, OP prognosis Fair but recurrent poor Response to treatment fair poor NSIP? (early) DAD (late) DAD, diffuse alveolar damage; NSIP, nonspecific interstitialpneumonia; OP, organizing pneumonia; UIP, usual interstitial pneumonia; Modified from Mimori T, Nakashima R, Hosono Y. Curr Rheumatol Rep. 2012;14(3):264-74
19 Anti-MJ/NXP-2 NXP-2 (nuclear matrix protein 2) MORC-3 (microchidia family CW-type zinc finger protein 3)
20 Anti-MJ (NXP-2, MORC3) antibodies Ceribelli A et al., Arthritis Res Ther. 2012;14(2):R97 Ichimura Y et al., Ann Rheum Dis. 2012;71(5):710-3
21 Anti-MJ (NXP-2, MORC3) antibodies Target protein (MJ antigen) was identified as: NXP-2 (nuclear matrix protein 2) MORC-3 (microchidia family CW-type zinc finger protein 3) Diffuse nuclear distribution but accumulated in nuclear dots structure (promyelocytic leukemia body, PML body).
22 Anti-MJ (NXP-2, MORC3) antibodies are common in juvenile DM 1997 Oddis CV et al., abstract, Arthritis Rheum. 40(9 suupl):s Espada G et al., J Rheumatol 36: Gunawardena H et al., Arthritis Rheum. 2009;60 (6): USA, Argentina and UK 20-30% of juvenile DM had anti-mj associated with severe refractory DM, arthritis, calcinosis, gastrointestinal vasculitis
23 Anti-MJ (NXP-2, MORC3) in adult PM/DM Ceribelli A et al., Arthritis Res Ther. 2012;14(2):R97 58 (27DM, 25PM, 6 overlap) Italian 30% in DM and 8% in PM 6/10 male associated with young onset, calcinosis (3/10) and lack of heart and lung disease (0/10) Ichimura Y et al., Ann Rheum Dis. 2012;71(5): (445DM, 62PM) Japanese 1.6% of DM (6 cases) and 1.6% of PM (1 case) 7/8male No calcinosis 0/8 No ILD 0/8 Associated with malignancy 4/8 (6/8 age >50)
24 A difference in prevalence of myositis autoantibodies (dermatomyositis, DM) Caucasian American (n = 17) Italian (n = 27) Mexican (n = 56) Jo-1 18% 0 4% EJ 0% 4% 0 OJ PL Any synthetase 18% 4% 4% MJ (NXP-2) 6% 30% 4% p155/140 12% 8% 16% Mi-2 6% 4% 43% SRP 0% 0 2% Satoh M, Ceribelli A, Vazquez del-marcado M, unpublished
25 Autoantibodies that recognize UsnRNPs D-E-F-G but not other components???
26 Antibodies that immunoprecipitate D-E-F-G recognize SMN (survival of motor neuron) complex Satoh M, et al. Arthritis Rheum (In Press) 2011
27 Spinal muscular atrophy (SMA) Autosomal recessive neurodegenerative disorder caused by mutation or deletion of SMN (survival of motor neuron) gene Mutation/deletion of SMN induces: degeneration of spinal cord motor neurons atrophy of skeletal muscles generalized weakness
28 Autoimmune sera that immunoprecipitate D-E-F-G proteins stain Cajal body in immunofluorescence Human anti-sm mouse mab Cajal body Human anti-defg #1 h- anti-defg #2 h-anti-defg #3 Normal control Satoh M, et al. Arthritis Rheum (In Press) 2011
29 SMN (survival of motor neuron) complex plays a critical role in assembly of snrnps in Cajal body Matera et al. Nature Reviews Molecular Cell Biology 8, (March 2007)
30 Summary Several new autoantibody specificities that have distinct clinical significance have been described, mainly in DM. -- Anti-p155/p DM with malignancy -- Anti-MDA5/CADM140 ADM with rapidly progressive ILD Further studies will be necessary to confirm the and understand the differences in different race/countries. Immunoassays for clinically useful autoantibodies should become widely available to clinicians.
Autoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
More informationAutoantibodies andprognosis. Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic
Autoantibodies andprognosis Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic HeterogeneityofIIMs Diagnosis Polymyositis Dermatomyositis IBM Necrotising myopathy Paraneoplastic Amyopathic
More informationSignificance of antibody testing in idiopathic inflammatory myopathies
2/0/20 Significance of antibody testing in idiopathic inflammatory myopathies Jiří Vencovský Institute of Rheumatology, Prague Diagnosis Polymyositis Juvenile DM (JPM) Paraneoplastic Myositis in overlap
More informationUtility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting
International Journal of Clinical Rheumatology Review ositis Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting Autoantibodies directed against nuclear or cellular
More informationClinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Rheumatoid Factor
More informationAutoantibodies in Idiopathic Inflammatory Myopathies. Vidya Limaye Rheumatology Department Royal Adelaide Hospital
Autoantibodies in Idiopathic Inflammatory Myopathies Vidya Limaye Rheumatology Department Royal Adelaide Hospital Idiopathic Inflammatory Myopathies (IIM) Heterogeneous group of systemic autoimmune syndromes
More informationDisappearance of anti-mda-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission
RHEUMATOLOGY Rheumatology 2012;51:800 804 doi:10.1093/rheumatology/ker408 Advance Access publication 30 December 2011 Concise report Disappearance of anti-mda-5 autoantibodies in clinically amyopathic
More informationAutoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically Amyopathic Dermatomyositis
ARTHRITIS & RHEUMATISM Vol. 52, No. 5, May 2005, pp 1571 1576 DOI 10.1002/art.21023 2005, American College of Rheumatology Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically
More informationIdiopathic inflammatory myopathies
Myositis and cancer Idiopathic inflammatory myopathies Primary idiopathic polymyositis Primary idiopathic dermatomyositis Juvenile poly/dermatomyositis Myositis associated with another CTD Myositis associated
More informationThis month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.
February 20, 2017 Client Letter Test Update February 2017 Dear Colleague: This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma
More informationPrevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-mda-5) autoantibody in Brazilian patients with dermatomyositis *
Investigation 517 Particular characteristics Soares de Sá BC, of atopic Moredo eczema LF, Gomes in tropical EE, de environments. Araújo ESS, Duprat The Tropical JP Environment... 517 s Prevalence and reactivity
More informationWhat are Autoantibodies and how do they work in Myositis?
What are Autoantibodies and how do they work in Myositis? Neil McHugh, University of Bath and Royal National Hospital for Rheumatic Diseases Orlando September 2015 Royal National Hospital for Rheumatic
More informationClinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies
CME Review Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies Autoantibodies to various cellular constituents are detected in the sera of patients
More informationWhat your autoantibodies tell us about your disease. Mark Gourley, MD
What your autoantibodies tell us about your disease Mark Gourley, MD The Importance of the Immune System Defends us against foreign invaders Self (cancer) and Nonself (virus, bacteria, etc.) But, if the
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationCASE REPORT. Introduction. Case Report
doi: 10.2169/internalmedicine.9553-17 http://internmed.jp CASE REPORT Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated
More informationMyositis 101. Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic, Rochester, MN
Myositis 101 Steven R. Ytterberg, M.D. Rheumatology Mayo Clinic, Rochester, MN Myositis Association Annual Conference Louisville, KY Sept. 6 & 7, 2018 Disclosures Consulting: Dynavax Pfizer Off-label use:
More informationE vidence for a significant myositis cancer association has
1345 EXTENDED REPORT The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis Hector Chinoy, Noreen Fertig, Chester V Oddis, William E R Ollier, Robert
More informationClinical Laboratory. [None
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG
More informationStrong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients
Strong correlation between cancer progression and anti-transcription intermediary factor γ antibodies in dermatomyositis patients M. Ogawa-Momohara, Y. Muro, T. Mitsuma 2, M. Katayama 3, K. Yanaba 4, M.
More informationClinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139
More informationClinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody
Cace report Clinical features of seven Japanese patients with anti-pl- antibody frequent positivity for anti-cyclic citrullinated peptide antibody Yoichiro Akiyama 1, Takao Nagashima 1, Masahiro Iwamoto
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More informationDermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan
CASE REPORT Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan Kenichiro Tokunaga 1 and Noboru Hagino 2 Abstract We performed a retrospective
More informationCLINICAL PRACTICE Clinical Vignettes Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin
CLINICAL PRACTICE Clinical Vignettes Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin Lori W. Lee, PhD 1, Neera S. Narang, MD 2, Anna Postolova, MD 2, Nicole Seminara, MD 4, and
More informationMyositis and Autoimmune ILD
Myositis and Autoimmune ILD 2018 AURA Annual Meeting Sedona, Arizona June 2, 2018 Chester V. Oddis, MD Director, Myositis Center University of Pittsburgh Disclosures Genentech: Clinical trial support Idera:
More informationDermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine
Dermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville Learning Objectives
More informationTools to Aid in the Accurate Diagnosis of. Connective Tissue Disease
Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,
More informationPL-7 and Anti-Jo-1 Antibodies. publication is available at link.sp
NAOSITE: Nagasaki University's Ac Title Author(s) Comparison of Pulmonary Involvement PL-7 and Anti-Jo-1 Antibodies Tomonaga, Masaomi; Sakamoto, Noriho Tomoyuki; Harada, Tatsuhiko; Nakash Shintaro; Horai,
More informationHUNGARIAN MYOSITIS COHORT
CLINICAL ADVANCES OF ANTI- TIF1Γ AUTOANTIBODY IN A HUNGARIAN MYOSITIS COHORT Melinda Nagy-Vincze 1, Zoltán Griger 1, Levente Bodoki 1, Zsuzsa Szankai 1, Zoe E. Betteridge 2, Katalin Dankó 1 1 University
More informationThe many faces of myositis. Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands
The many faces of myositis Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands Outline of the presentation Classification Diagnosis Therapy Prognosis Diagnostic criteria
More informationClinical Study A Clinical Analysis of Risk Factors for Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myopathy
Clinical and Developmental Immunology Volume 2013, Article ID 648570, 4 pages http://dx.doi.org/10.1155/2013/648570 Clinical Study A Clinical Analysis of Risk Factors for Interstitial Lung Disease in Patients
More informationClinical and Pathological Findings of Interstitial Lung Disease Patients with Anti-Aminoacyl-tRNA Synthetase Autoantibodies
ORIGINAL ARTICLE Clinical and Pathological Findings of Interstitial Lung Disease Patients with Anti-Aminoacyl-tRNA Synthetase Autoantibodies Yoshimizu Koreeda 1, Ikkou Higashimoto 1, Masuki Yamamoto 1,
More informationIdiopathic inflammatory myopathies and the lung
EUROPEAN RESPIRATORY UPDATE IDIOPATHIC INFLAMMATORY MYOPATHIES Idiopathic inflammatory myopathies and the lung Jean-Christophe Lega 1,2, Quitterie Reynaud 1, Alexandre Belot 3, Nicole Fabien 4, Isabelle
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationNovel autoantibodies and clinical phenotypes in adult and juvenile myositis
REVIEW Novel autoantibodies and clinical phenotypes in adult and juvenile myositis Zoe E Betteridge*, Harsha Gunawardena and Neil J McHugh Abstract Autoantibodies targeting intracellular proteins involved
More informationCASE REPORT. Abstract. Introduction
CASE REPORT The Clinical Characteristics of Two Anti-OJ (Anti-IsoleucyltRNA Synthetase) Autoantibody-Positive Interstitial Lung Disease Patients with Polymyositis/Dermatomyositis Kei Kunimasa 1,8, Machiko
More informationdermatomyositis: report of a case.
Living-donor lobar lung transplanta Titleinterstitial pneumonia associated w dermatomyositis: report of a case., Tsuyoshi; Bando, Toru; Fujin Author(s) Fengshi; Sasano, Hajime; Yukawa, Na Tsuneyo; Date,
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationCitation Clinical rheumatology (2011), 30(3)
A case of antisynthetase syndrome i Titlepatient with anti-pl-12 antibody fo etanercept. Ishikawa, Yuki; Yukawa, Naoichiro; Author(s) Ohmura, Koichiro; Fujii, Takao; Usu Tsuneyo Citation Clinical rheumatology
More informationClinical Study Anti-Ro52 Antibodies and Interstitial Lung Disease in Connective Tissue Diseases Excluding Scleroderma
International Scholarly Research Network ISRN Rheumatology Volume 2012, Article ID 415272, 4 pages doi:10.5402/2012/415272 Clinical Study Anti-Ro52 Antibodies and Interstitial Lung Disease in Connective
More informationClinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
doi: 10.2169/internalmedicine.1516-18 http://internmed.jp CASE REPORT Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis Noriho
More informationBench to bedside review of myositis autoantibodies
https://doi.org/10.1186/s12948-018-0084-9 Clinical and Molecular Allergy REVIEW Open Access Bench to bedside review of myositis autoantibodies Boaz Palterer *, Gianfranco Vitiello, Alessia Carraresi, Maria
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091593 Age 25 Years Gender Male 30/8/2017 91600AM 30/8/2017 93946AM 31/8/2017 84826AM Ref By Final COLLAGEN DISEASES ANTIBODY ANEL ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF),
More information*Pari Basharat ABSTRACT OVERVIEW OF IDIOPATHIC INFLAMMATORY MYOPATHIES
IDIOPATHIC INFLAMMATORY MYOPATHIES: ASSOCIATION WITH OVERLAP MYOSITIS AND SYNDROMES: CLASSIFICATION, CLINICAL CHARACTERISTICS, AND ASSOCIATED AUTOANTIBODIES *Pari Basharat University of Western Ontario,
More informationClinical characteristics of Japanese patients with anti-pl-7 (anti-threonyl-trna synthetase) autoantibodies
Clinical characteristics of Japanese patients with anti-pl-7 (anti-threonyl-trna synthetase) autoantibodies S. Sato 1, M. Hirakata 1, M. Kuwana 2, K. Nakamura 1, A. Suwa 1, S. Inada 3, T. Mimori 4, Y.
More informationCorrespondence should be addressed to Yasuhiro Shimojima;
Hindawi Case Reports in Rheumatology Volume 2017, Article ID 5386797, 6 pages https://doi.org/10.1155/2017/5386797 Case Report Effective Administration of Rituximab in Anti-MDA5 Antibody Positive Dermatomyositis
More informationSkin Manifestations of Dermatomyositis. Victoria P. Werth, M.D. University of Pennsylvania. Chief, Dermatology Philadelphia VAMC
Skin Manifestations of Dermatomyositis Victoria P. Werth, M.D. University of Pennsylvania Chief, Dermatology Philadelphia VAMC Overview Pathogenesis: Inflammatory cells in the skin, Interferon, medications
More informationTest Name Results Units Bio. Ref. Interval
135091660 Age 44 Years Gender Male 29/8/2017 120000AM 29/8/2017 100219AM 29/8/2017 105510AM Ref By Final EXTRACTABLENUCLEAR ANTIGENS (ENA), QUANTITATIVE ROFILE CENTROMERE ANTIBODY, SERUM 20-30 Weak ositive
More informationSMA IS A SEVERE NEUROLOGICAL DISORDER [1]
SMA OVERVIEW SMA IS A SEVERE NEUROLOGICAL DISORDER [1] Autosomal recessive genetic inheritance 1 in 50 people (approximately 6 million Americans) are carriers [2] 1 in 6,000 to 1 in 10,000 children born
More informationInflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist
Inflammatory Myopathies 4 th year MBBS Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist Case A 64 woman presents with erythematous itchy rash over back of hands & forehead. For 1 month
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationDiscovery, Understanding, and Progress in Myositis
Discovery, Understanding, and Progress in Myositis Steven Ytterberg, M.D. TMA Annual Patient Conference New Orleans, LA Sept. 2, 2016 Disclosures Financial: Dynavax Corp. Pfizer Mallinckrodt American Board
More informationAtlas of Antinuclear Antibodies
Fluorescence patterns of cytoplasmic autoantigens There are many important organelles in the cytoplasm which fulfill various functions of the cell as described in section 1. Various autoantibodies, known
More informationCalcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options
Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options M. Fredi 1, F. Bartoli 1,2, I. Cavazzana 1, A. Ceribelli 3, N. Carabellese 1, A. Tincani 1,2, M. Satoh 4, F.
More informationThe Power of the ANA. April 2018 Emily Littlejohn, DO MPH
Emergent Rheumatologic Diseases and Disorders for Primary Care. The Power of the ANA April 2018 Emily Littlejohn, DO MPH Question 1: the ANA test is: A) A screening test with high specificity to diagnose
More informationNaomi Yoshida, Shinjiro Kaieda, Kumi Tomozoe, Morihiro Tajiri, Daisuke Wakasugi, Masaki Okamoto, Masaki Tominaga, Hiroaki Ida and Tomoaki Hoshino
CASE REPORT An Autopsy Case of Anti-melanoma Differentiation-associated Gene-5 Antibody-positive Clinical Amyopathic Dermatomyositis Complicated by Rapidly Progressive Interstitial Lung Disease Naomi Yoshida,
More informationThe lung as a possible target for the immune reaction in myositis
REVIEW The lung as a possible target for the immune reaction in myositis Sonye K Danoff 1 and Livia Casciola-Rosen 2 * Abstract Interstitial lung disease is a common manifestation of autoimmune myositis
More informationINTRODUCTION ABSTRACT
/, 2017, Vol. 8, (No. 44), pp: 76129-76140 Assessment of anti-mda5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial
More informationIDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS. Franclo Henning Division of Neurology Tygerberg Hospital
IDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS Franclo Henning Division of Neurology Tygerberg Hospital Classification systems Clinical (Bohan and Peter) Clinico-pathological (Dalakas & others)
More informationNovel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies Analysis of 100 French Canadian Patients Yves Troyanov, MD, Ira N. Targoff, MD, Jean-Luc
More informationIdiopathic inflammatory myopathies excluding inclusion body myositis
Idiopathic inflammatory myopathies excluding inclusion body myositis Marianne de Visser, Dept. of Neurology, Academic Medical Centre, Amsterdam, The Netherlands The idiopathic inflammatory myopathies (IIMs),
More informationFaculty of Medicine, Titu Maiorescu University, Bucharest, Romania b. Dr. Ion Stoia Clinical Center for Rheumatic Diseases, Bucharest, Romania c
Mædica - a Journal of Clinical Medicine MAEDICA a Journal of Clinical Medicine 2016; 11(6): 130-135 STATE OF THE ART New Insights into Antisynthetase Syndrome Manole COJOCARU a,b ; Inimioara Mihaela COJOCARU
More informationREVIEW. Sarah L Tansley 1, Neil J McHugh 1 and Lucy R Wedderburn 2 * Abstract
REVIEW Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Sarah L Tansley 1, Neil J McHugh
More informationThomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine. Disclosures: None
Thomas A. Medsger, Jr., MD University of Pittsburgh School of Medicine Disclosures: None 4000+ patients enrolled 1972- present; 5+ visits per patient; 20,000+ patient years of follow- up All clinical and
More informationL. Nandini Moorthy, MD MS 2012
L. Nandini Moorthy, MD MS 2012 L Nandini Moorthy, MD MS 09 17 yo Ashkenazi male with proximal muscle pain and weakness, mild malar erythema and erythema over knees and dorsal aspect of PIPs Mild tenderness
More informationRare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy
ARTIGO ORIGINAL Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllösi L, Jobanputra R,
More informationInterstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology
Interstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology Robert G Cooper Prof of Medicine (Muscle and Rheumatology) Normal Alveolar Physiology Contrast with ILD Pathologies Impairing
More informationAnti-synthetase syndrome
Anti-synthetase syndrome Floranne C. Ernste, M.D. The Myositis Association Annual Conference Louisville, KY September 7, 2018 2017 MFMER slide-1 Disclosures Octapharma: clinical trial support Genentech:
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationDiagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016
Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016 A/Prof Tamera Corte TSANZ Annual Conference: Perth 2016 Royal Prince Alfred Hospital, Sydney, Australia Sydney Medical School, University
More informationPredictors of Clinical Improvement in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis
ARTHRITIS & RHEUMATOLOGY Vol. 66, No. 3, March 2014, pp 740 749 DOI 10.1002/art.38270 2014, American College of Rheumatology Predictors of Clinical Improvement in Rituximab-Treated Refractory Adult and
More informationThe Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome
doi: 10.2169/internalmedicine.8955-17 http://internmed.jp CASE REPORT The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome Yoshimasa Hachisu 1, Yasuhiko Koga 1, Noriaki Sunaga 1,2, Chiharu
More informationClinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis
RHEUMATOLOGY Rheumatology 2015;54:784 791 doi:10.1093/rheumatology/keu385 Advance Access publication 6 October 2014 Original article Clinical and laboratory features of fatal rapidly progressive interstitial
More informationClinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease
Rheumatology 2002;41:1268 1272 Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositisudermatomyositis: correlation with interstitial lung disease H. Ihn, Y. Asano, M.
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationCASE REPORT. Case Report. Introduction
doi: 1.2169/internalmedicine.7-18 Intern Med Advance Publication http://internmed.jp CASE REPORT A Case of a Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who
More informationIdentification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study
Yang et al. Arthritis Research & Therapy (2017) 19:259 DOI 10.1186/s13075-017-1469-8 RESEARCH ARTICLE Open Access Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic
More informationMarcela Gran Pina Cruellas, Vilma dos Santos Trindade Viana, Maurício Levy-Neto, Fernando Henrique Carlos de Souza, Samuel Katsuyuki Shinjo
CLINICAL SCIENCE Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis Marcela Gran Pina Cruellas,
More informationUpdate on myositis-specific and myositis-associated autoantibodies Ira N. Targoff, MD
Update on myositis-specific and myositis-associated autoantibodies Ira N. Targoff, MD Myositis-specific autoantibodies or myositis-associated autoantibodies can often be found in serum of patients with
More informationAutoantibodies panel ANA
Autoantibodies panel ANA Anti-nuclear antibodies, ANA screening General: Anti-nuclear antibodies (ANA) contain all kinds of autoantibodies against nuclear antigens. Their targets are cell components in
More informationComparison of Performance of ELISA with Indirect Immunofluoresence for the Testing of Antinuclear Antibodies
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 12 (2016) pp. 423-427 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.512.046
More informationIdiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya
Idiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya I.W, 28 YRS, FEMALE SHOP STEWARD Referred to KNH on 16/06/09 from Thika Nursing Home Weakness
More informationEXTENDED REPORT. Clinical and epidemiological research
Additional supplementary tables is published online only. To view the fi les please visit the journal online (http://ard.bmj.com/ content/71/6.toc). 1 Rheumatic Diseases Centre, Manchester Academic Health
More informationPOLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by
POLYMYOSITIS (PM) DERMATOMYOSITIS (DM) Body myositis Eosinophilic myositis Giant cell myositis Focal / localised myositis Myopathies caused by infections, drugs, toxins Definition Epidemiology Pathogenesis
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationMechanic s hands revisited: is this sign still useful for diagnosis in patients with lung involvement of collagen vascular diseases?
Sohara et al. BMC Research Notes 2014, 7:303 RESEARCH ARTICLE Open Access Mechanic s hands revisited: is this sign still useful for diagnosis in patients with lung involvement of collagen vascular diseases?
More informationSENSITIVITY AND SPECIFICITY OF ANTI-Jo-1 ANTIBODIES IN AUTOIMMUNE DISEASES WITH MYOSITIS
292 ARTHRITIS & RHEUMATISM Vol. 39, No. 2, February 1996, pp 292-296 1996, American College of Rheumatology SENSITIVITY AND SPECIFICITY OF ANTI-Jo-1 ANTIBODIES IN AUTOIMMUNE DISEASES WITH MYOSITIS DOLORES
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationThe predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease
Sugiyama et al. Arthritis Research & Therapy (2018) 20:7 DOI 10.1186/s13075-017-1506-7 RESEARCH ARTICLE Open Access The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial
More informationmyopathy and interstitial lung dise
NAOSITE: Nagasaki University's Ac Title Author(s) Citation A case of primary Sjögren's syndrom myopathy and interstitial lung dise Koga, Tomohiro; Kouhisa, Yukiko; Na Akinari; Motomura, Masakatsu; Kawak
More informationSignificance of Myositis Autoantibody in Patients with Idiopathic Interstitial Lung Disease
Original Article http://dx.doi.org/10.3349/ymj.2015.56.3.676 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 56(3):676-683, 2015 Significance of Myositis Autoantibody in Patients with Idiopathic Interstitial
More informationDiseases of Muscle and Neuromuscular Junction
Diseases of Muscle and Neuromuscular Junction Diseases of Muscle and Neuromuscular Junction Neuromuscular Junction Muscle Myastenia Gravis Eaton-Lambert Syndrome Toxic Infllammatory Denervation Atrophy
More informationAcute Respiratory Distress Syndrome as the Initial Clinical Manifestation of an Antisynthetase Syndrome
CASE REPORT http://dx.doi.org/10.4046/trd.2016.79.3.188 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2016;79:188-192 Acute Respiratory Distress Syndrome as the Initial Clinical Manifestation
More informationJUVENILE DERMATOMYOSITIS
JUVENILE DERMATOMYOSITIS - how to diagnose, how to treat? Miloš Nikolić, MD, PhD Professor and Chairman Department of Dermatology, Division of Pediatric Dermatology University of Belgrade, School of Medicine,
More informationNATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies
NATIONAL LABORATORY HANDBOOK Laboratory Testing for Antinuclear antibodies Document reference number CSPD013/2018 Document developed by National Clinical Programme for Pathology Revision number Version
More informationFavorable rituximab response in patients with refractory idiopathic inflammatory myopathies
de Souza et al. Advances in Rheumatology (2018) 58:31 https://doi.org/10.1186/s42358-018-0030-z Advances in Rheumatology RESEARCH Favorable rituximab response in patients with refractory idiopathic inflammatory
More informationClinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis
CHEST Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis Hiroshi Mukae, MD, PhD; Hiroshi Ishimoto, MD; Noriho Sakamoto,
More informationChapter 2 Classification of Idiopathic Inflammatory Myopathies
Chapter 2 Classification of Idiopathic Inflammatory Myopathies Frederick W. Miller Abstract Although it has been long recognized that inflammatory muscle disease of unknown etiology may present clinically
More information